Emlozin-L
Generic Name
Emlozin-L 10 mg Tablet
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| emlozin l 10 mg tablet | ৳ 25.00 | ৳ 250.00 |
Description
Overview of the medicine
Emlozin-L 10 mg Tablet is an oral antidiabetic medication used to improve glycemic control in adults with type 2 diabetes mellitus. It belongs to a class of drugs called SGLT2 inhibitors, which help the kidneys remove glucose from the body through urine.
Uses & Indications
Dosage
Adults
The recommended starting dose is 10 mg once daily, taken in the morning, with or without food. The dose may be increased to 25 mg once daily based on glycemic control and tolerability.
Elderly
No dose adjustment is required based on age. However, renal function should be considered, as elderly patients may have reduced renal function.
Renal_impairment
No dose adjustment is needed for mild to moderate renal impairment. Initiation is not recommended for eGFR < 30 mL/min/1.73m². Not recommended for end-stage renal disease or dialysis.
How to Take
Take orally once daily in the morning, with or without food. Swallow the tablet whole with water.
Mechanism of Action
Emlozin-L selectively inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal tubules, reducing glucose reabsorption and increasing urinary glucose excretion. This leads to a reduction in blood glucose levels independently of insulin secretion.
Pharmacokinetics
Onset
Within hours of administration, significant glycemic reduction observed.
Excretion
Excreted predominantly in urine (approx. 50-60%) and feces (approx. 40-50%).
Half life
Approximately 10-15 hours, allowing for once-daily dosing.
Absorption
Rapidly absorbed after oral administration, peak plasma concentration reached within 1-2 hours. High oral bioavailability.
Metabolism
Primarily metabolized by O-glucuronidation in the liver to inactive metabolites.
Side Effects
Contraindications
- Hypersensitivity to Emlozin-L or any of its components.
- Severe renal impairment, end-stage renal disease, or patients on dialysis.
- Diabetic ketoacidosis.
Drug Interactions
Diuretics
Increased risk of dehydration and hypotension.
ACE Inhibitors/ARBs
May increase risk of hypotension due to diuretic effect.
Insulin and Insulin Secretagogues (e.g., sulfonylureas)
Increased risk of hypoglycemia when used concomitantly. A lower dose of insulin or sulfonylurea may be required.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
In the event of an overdose, symptomatic and supportive treatment should be initiated. Emlozin-L is not expected to be dialyzable.
Pregnancy & Lactation
Not recommended during pregnancy, especially during the second and third trimesters, due to potential adverse effects on fetal kidney development. It is unknown whether Emlozin-L is excreted in human milk; therefore, it is not recommended during breastfeeding.
Side Effects
Contraindications
- Hypersensitivity to Emlozin-L or any of its components.
- Severe renal impairment, end-stage renal disease, or patients on dialysis.
- Diabetic ketoacidosis.
Drug Interactions
Diuretics
Increased risk of dehydration and hypotension.
ACE Inhibitors/ARBs
May increase risk of hypotension due to diuretic effect.
Insulin and Insulin Secretagogues (e.g., sulfonylureas)
Increased risk of hypoglycemia when used concomitantly. A lower dose of insulin or sulfonylurea may be required.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
In the event of an overdose, symptomatic and supportive treatment should be initiated. Emlozin-L is not expected to be dialyzable.
Pregnancy & Lactation
Not recommended during pregnancy, especially during the second and third trimesters, due to potential adverse effects on fetal kidney development. It is unknown whether Emlozin-L is excreted in human milk; therefore, it is not recommended during breastfeeding.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 to 36 months from manufacturing date.
Availability
Available in pharmacies nationwide
Approval Status
DGDA Approved
Patent Status
On Patent
Clinical Trials
Extensive clinical trials (e.g., EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, EMPA-KIDNEY) have demonstrated the efficacy and safety of SGLT2 inhibitors like Emlozin-L in glycemic control, cardiovascular outcomes, and renal protection.
Lab Monitoring
- Renal function (eGFR) before initiation and periodically thereafter.
- Blood glucose levels and HbA1c.
- Electrolyte levels (if concerns about dehydration).
Doctor Notes
- Educate patients on the signs and symptoms of DKA, dehydration, and genitourinary infections.
- Monitor renal function before and periodically during treatment.
- Counsel patients on proper hygiene and adequate fluid intake.
- Consider dose adjustment for concomitant use with insulin or sulfonylureas to minimize hypoglycemia risk.
Patient Guidelines
- Take Emlozin-L exactly as prescribed by your doctor.
- Stay well-hydrated by drinking plenty of fluids.
- Maintain good personal hygiene, especially genital hygiene, to reduce the risk of infections.
- Be aware of the symptoms of dehydration, UTIs, and DKA and seek medical attention if they occur.
Missed Dose Advice
If a dose is missed, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Emlozin-L has little to no influence on the ability to drive or use machines. However, if used in combination with insulin or sulfonylureas, it may increase the risk of hypoglycemia, which could impair driving ability. Patients should be advised to take precautions to avoid hypoglycemia.
Lifestyle Advice
- Follow a balanced diet and regular exercise regimen as advised by your healthcare provider.
- Monitor your blood sugar levels regularly.
- Limit alcohol consumption.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.